hepatocellular carcinoma
Survey only people who would be treated: cirrhosis of any cause (Child-Pugh A–B, or C if transplant candidate) and chronic HBV in the CASL 2025 groups. US + AFP every 6 months. Lesion ≥1 cm or AFP ≥20 / rising → multiphase CT or MRI. In cirrhosis or HBV, LI-RADS 5 = HCC without biopsy. Staging and treatment follow BCLC: resection, ablation or transplant (early) → TACE (intermediate) → atezolizumab–bevacizumab or durvalumab–tremelimumab (advanced) → best supportive care.
who to survey
Surveillance only helps if the patient would be a candidate for treatment.
| group | survey? |
|---|---|
| cirrhosis, any aetiology, Child-Pugh A–B | yes |
| Child-Pugh C | only if transplant candidate; all listed patients |
| HCV cirrhosis after SVR | yes — lifelong |
| HBV without cirrhosis (CASL 2025) | men ≥40 · women ≥50 · African ancestry ≥30 · first-degree relative with HCC (from 40, or 10 years before relative’s age at diagnosis) · HIV coinfection ≥40 · HDV coinfection ≥40 (earlier if F3+) |
| HCV post-SVR with F3, no cirrhosis | no (not routine) |
| MASLD with advanced fibrosis, no cirrhosis | no (not routine) |
| haemochromatosis without cirrhosis | no |
| life-limiting comorbidity not fixable by transplant | no |
HBV surveillance continues on antivirals and even after HBsAg loss if cirrhotic.
how
- Ultrasound + AFP every 6 months. CT/MRI and other biomarkers are not routine.
- Report US visualisation quality; poor visualisation (obesity, MASLD, nodular liver) → contrast MRI or multiphase CT instead.
- Underuse is the main failure — recall systems and outreach improve adherence.
recall
| finding | next step |
|---|---|
| lesion <1 cm | repeat US + AFP in 3–6 months; stable ×2 → back to 6-monthly |
| lesion ≥1 cm | multiphase CT or contrast MRI |
| AFP ≥20 µg/L or rising | multiphase CT or contrast MRI |
diagnosis
In cirrhosis or chronic HBV, HCC is diagnosed on imaging alone — arterial-phase hyperenhancement with washout and/or capsule (LI-RADS). Outside these groups, imaging isn’t accurate enough → biopsy.
| LI-RADS | management |
|---|---|
| LR-1 / LR-2 | benign / probably benign → routine surveillance |
| LR-3 | repeat CT/MRI in 3–6 months |
| LR-4 | multidisciplinary review; repeat imaging ≤3 months or biopsy |
| LR-5 | HCC — treat without biopsy |
| LR-M | malignant, not HCC-specific → biopsy (cholangiocarcinoma, mixed tumour) |
AFP alone doesn’t diagnose HCC.
staging and treatment
Stage with multiphase CT/MRI of the abdomen + CT chest (beyond stage 0). No routine PET or bone scan. BCLC integrates tumour burden, liver function (Child-Pugh, portal hypertension) and ECOG.
flowchart TD
A[HCC] --> B{BCLC stage}
B -->|0–A: single or ≤3 nodules ≤3 cm, ECOG 0, preserved liver function| C{portal hypertension or decompensation?}
C -->|no| D[resection]
C -->|yes, within Milan| E[liver transplant]
C -->|not a surgical candidate| F[thermal ablation ≤3 cm · radioembolisation]
B -->|B: multinodular, ECOG 0| G[TACE]
B -->|C: vascular invasion or spread, ECOG 1–2| H[systemic therapy]
B -->|D: Child-Pugh C not transplantable, ECOG 3–4| I[best supportive care]
G -->|progression or unsuitable| H
- Resection: no cirrhosis, or well-compensated cirrhosis without CSPH.
- Transplant: early HCC with CSPH or decompensation (Milan: single ≤5 cm, or ≤3 nodules each ≤3 cm, no vascular invasion). Treats both the cancer and the cirrhosis. Bridging locoregional therapy while listed.
- Ablation (radiofrequency or microwave) = treatment of choice for ≤3 cm when surgery isn’t possible.
- TACE for BCLC B; radioembolisation an alternative.
- Systemic, Child-Pugh A, ECOG 0–1: atezolizumab + bevacizumab or durvalumab + tremelimumab first-line. Bevacizumab → EGD first; treat high-risk varices (≥1 banding session) or choose durvalumab–tremelimumab if recent GI bleed. Tyrosine kinase inhibitors (lenvatinib, sorafenib) when immunotherapy is contraindicated. Well-selected Child-Pugh B only.
- No adjuvant or neoadjuvant systemic therapy with resection or ablation — the IMbrave050 recurrence-free survival benefit didn’t hold up (AASLD 2025 update). Surveillance for recurrence is the standard after curative treatment.
- Child-Pugh C not transplantable → palliative care; advance care planning for all.
prevention
- HBV vaccination; treat HBV and cure HCV (lowers but doesn’t abolish risk).
- Weight, diabetes and alcohol control; stop smoking.
- Coffee associated with lower HCC risk — reasonable to encourage.
- Statins, aspirin and metformin: not for HCC prevention alone; don’t stop them in cirrhosis if otherwise indicated.
Prepared 2026-10-28. Not yet verified — check every number against the sources.